Subcutaneous Lecanemab Heads Toward May 2026 FDA Decision: What Practices Should Plan

Subcutaneous lecanemab is under FDA priority review for once-weekly at-home initiation, with a PDUFA action date of May 24, 2026. Here is what neurology practices should consider before the decision.

April 26, 2026 · 4 min read

Why Subcutaneous Lecanemab Is in the News

Subcutaneous lecanemab took a meaningful regulatory step forward on January 25, 2026, when the FDA accepted Eisai’s supplemental Biologics License Application (sBLA) for the autoinjector formulation as a once-weekly starting dose. The agency granted priority review and set a Prescription Drug User Fee Act (PDUFA) action date of May 24, 2026.

If approved, Leqembi Iqlik would become the first anti-amyloid therapy that can be initiated at home, eliminating the biweekly intravenous (IV) infusions currently required for the first 18 months of treatment. The FDA already cleared the same autoinjector for weekly maintenance dosing in August 2025, but initiation has remained a clinic-based procedure.

The Background

Lecanemab (Leqembi), a humanized IgG1 monoclonal antibody targeting amyloid-beta protofibrils, received traditional FDA approval for early symptomatic Alzheimer disease (AD) in July 2023. Treatment is currently initiated at 10 mg/kg IV every two weeks for 18 months.

After initiation, patients can transition to either monthly IV infusions or weekly 360 mg subcutaneous (SC) injections using the Iqlik autoinjector. The new application would shift the entire regimen — including initiation — to a 500 mg weekly SC dose delivered as two 250 mg injections.

The Evidence So Far on Subcutaneous Lecanemab

The sBLA is supported by data from a subcutaneous sub-study within the open-label extension (OLE) of the phase 3 Clarity AD trial (NCT03887455). The 500 mg weekly SC regimen produced plasma exposure within accepted bioequivalence limits relative to 10 mg/kg IV biweekly, with comparable amyloid clearance and biomarker effects.

The Clarity AD core study, published in NEJM in 2023, randomized 1,795 patients with mild cognitive impairment (MCI) or mild AD dementia. Lecanemab slowed cognitive decline on the Clinical Dementia Rating–Sum of Boxes (CDR-SB) by 27% at 18 months versus placebo (adjusted mean change 1.21 vs 1.66; difference −0.45; p=0.00005). The 48-month open-label extension reported a CDR-SB difference of −1.75 points compared with a matched Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort.

Amyloid-related imaging abnormalities (ARIA — brain edema or microhemorrhages on MRI) remain the principal safety concern. ARIA-E (edema) occurred in 12.6% of lecanemab-treated patients versus 1.7% on placebo. Risk is strongly tied to apolipoprotein E (ApoE) ε4 status: 6.5% of non-carriers, 11.6% of heterozygotes, and 34.5% of homozygotes. Most cases occurred within 3 to 6 months of initiation and resolved on follow-up MRI within four months.

Where Experts Disagree on Subcutaneous Lecanemab

Clinicians remain split on several practical questions. The first is whether at-home initiation is appropriate before the highest-risk ARIA window has passed. Investigators from Clarity AD have emphasized that radiographic ARIA, when it occurs, has not predicted faster decline.

“Those with ARIA are not progressing faster — they’re progressing numerically slower.” — Christopher van Dyck, MD, Director, Alzheimer’s Disease Research Unit, Yale University (Clarity AD investigator)

More cautious voices counter that the current FDA label requires enhanced clinical vigilance during the first 14 weeks of treatment, and that triaging suspected ARIA outside an infusion suite — where MRI access and rapid neurology contact are routine — has not been studied prospectively in a pivotal trial.

A second debate concerns patient selection. Some specialists argue that ApoE ε4 homozygotes, who face roughly a one-in-three risk of ARIA-E, should receive extensive pretreatment counseling or be excluded altogether. The current label requires ApoE ε4 testing prior to initiation, but the threshold for proceeding remains a clinical judgment call.

The Practical Question for Clinicians

The practical question is what neurology practices should plan now, before the May 24, 2026 decision. Three concrete steps are reasonable while awaiting regulatory clarity.

First, audit current candidates: confirm amyloid status, ApoE ε4 genotype, baseline brain MRI, and absence of concurrent anticoagulation that would raise bleeding risk during ARIA. Second, build patient and caregiver injection-training materials and consent documents in anticipation of an at-home initiation pathway.

Third, plan MRI surveillance scheduling separately from any infusion appointment — the current label requires monitoring MRIs before the 5th, 7th, and 14th doses, and that schedule is unlikely to change for subcutaneous lecanemab initiation. Practices should also follow CMS coverage announcements closely; how Medicare’s registry-participation requirement applies to a self-administered formulation will be a key implementation question.

What to Watch For

The May 24, 2026 PDUFA decision on subcutaneous lecanemab — approval, complete response letter, or extension
Any updates to the boxed warning text, ApoE ε4 testing language, or MRI surveillance schedule
Real-world ARIA rates from registries comparing IV and SC initiation cohorts
CMS guidance on coverage and registry requirements for at-home initiation

Sources

Eisai Co., Ltd. and Biogen. FDA Accepts LEQEMBI IQLIK (lecanemab-irmb) sBLA as a Subcutaneous Starting Dose for Early Alzheimer’s Disease under Priority Review. Press release, January 25, 2026. Eisai sBLA Acceptance Press Release (January 25, 2026)
van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer’s Disease. N Engl J Med. 2023;388:9–21. van Dyck et al., NEJM 2023 — Lecanemab in Early Alzheimer’s Disease
Honig LS, Barakos J, Dhadda S, et al. Updated Safety Results from Phase 3 Lecanemab Study in Early Alzheimer’s Disease. Alzheimer’s Research & Therapy. 2024;16:105. Updated Safety Results — Alzheimer’s Research & Therapy (2024)
Eisai Co., Ltd. and Biogen. FDA Approves LEQEMBI IQLIK Subcutaneous Injection for Maintenance Dosing. Press release, August 29, 2025. Eisai Subcutaneous Maintenance Approval Press Release (August 29, 2025)
Dyck CH, Swanson CJ, Li D, et al. The Lecanemab Clarity AD Open-Label Extension in Early Alzheimer’s Disease: Initial Findings From the 48-Month Analysis. Alzheimer’s & Dementia. 2025. Clarity AD 48-Month Open-Label Extension Findings
NeurologyLive. Priority Review Granted for Weekly Subcutaneous Lecanemab Dosing in Early Alzheimer Disease. February 4, 2026. NeurologyLive — Priority Review Granted for Weekly Subcutaneous Lecanemab
Practical Neurology. FDA to Consider the Approval of a Subcutaneous Starting Dose for Lecanemab. January 26, 2026. Practical Neurology — Subcutaneous Starting Dose Coverage